Skip to main content
. 2019 Oct 21;317(6):F1695–F1706. doi: 10.1152/ajprenal.00147.2019

Fig. 4.

Fig. 4.

Pelvic region sensitivity testing with calibrated von Frey filaments was determined in littermate wild-type (WT) mice and transgenic mice with chronic urothelial overexpression of nerve growth factor (NGF-OE) before and after intravesical instillation of the transient receptor potential vanilloid family member 4 (TRPV4) receptor antagonist HC-067047 (1 µM). Stimulation was confined to the lower abdominal area overlying the urinary bladder. NGF-OE mice had a significantly (*P ≤ 0.01) increased pelvic response frequency with all von Frey filaments (0.1–4 g) tested compared with littermate WT mice. In NGF-OE mice, intravesical instillation of HC-067047 (1 µM) significantly (*P ≤ 0.01) reduced pelvic response frequency with all von Frey filaments tested compared with NGF-OE mice treated with vehicle (saline, 0.9%). No changes in pelvic sensitivity were observed in WT mice after intravesical instillation of HC-067047. All somatic testing was performed in a blinded manner. Values are means ± SE; n = 10 for each group.